Ofatumumab for the treatment of chronic lymphocytic leukaemia in patients who are refractory to fludarabine and alemtuzumab: a critique of the submission from GSK
about
Ofatumumab for the treatment of chronic lymphocytic leukaemia in patients who are refractory to fludarabine and alemtuzumab: a critique of the submission from GSK
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Ofatumumab for the treatment o ...... que of the submission from GSK
@ast
Ofatumumab for the treatment o ...... que of the submission from GSK
@en
Ofatumumab for the treatment o ...... que of the submission from GSK
@nl
type
label
Ofatumumab for the treatment o ...... que of the submission from GSK
@ast
Ofatumumab for the treatment o ...... que of the submission from GSK
@en
Ofatumumab for the treatment o ...... que of the submission from GSK
@nl
prefLabel
Ofatumumab for the treatment o ...... que of the submission from GSK
@ast
Ofatumumab for the treatment o ...... que of the submission from GSK
@en
Ofatumumab for the treatment o ...... que of the submission from GSK
@nl
P2093
P356
P1476
Ofatumumab for the treatment o ...... que of the submission from GSK
@en
P2093
P356
10.3310/HTA15SUPPL1/07
P407
P478
15 Suppl 1
P50
P577
2011-05-01T00:00:00Z